 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Eurespal, Pneumorel |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 90%[1] |
| Eliminationhalf-life | 14–16 hours |
| Excretion | Urine (90%), feces (~10%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.023.411 |
| Chemical and physical data | |
| Formula | C15H20N2O2 |
| Molar mass | 260.337 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Fenspiride (INN, brand namesEurespal,Pneumorel and others) is anoxazolidinonespiro compound used as a drug in the treatment of certain respiratory diseases.[2] The pharmacotherapeutic classification isantitussives. In Russia it was approved for the treatment of acute and chronic inflammatory diseases ofENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment ofasthma.[3]Russia,Romania,France and other European countries withdrew fenspiride-based drugs from the market due to the risk ofQT prolongation andtorsades de pointes.[4] Fenspiride is known to have activity as analpha-1 blocker,H1 antagonist, it also inhibitsPDE3,PDE4,PDE5 with-logIC50 values of 3.44, 4.16, 3.8 respectively.[5]